|
|
 |
Systemic anti-infective
|
 |
Antiviral agent
|
 |
Treatment for initial occurrence of genital herpes: 200 mg every 4 hours, 5 times a day for 10 days. Chronic suppressive therapy: 400 mg 2 times a day for up to 12 months. Alternative regimens: 200 mg 3 times a day for 5 days. Herpes Zoster: 800 mg 5 times a day for 5-7 days. Chickenpox: 20 mg/kg 4 times a day for 5 days.
|
 |
Category B
|
 |
Nausea, vomiting, anemia, headache, Diarrhea, abdominal pain, and rash.
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
 |
|
|
